Tumorigenesis News and Research

RSS

Tumorigenesis is the process involved in the production of a new tumor or tumors.

Researcher argues against use of Cop1-inhibitory drugs for cancer treatment

Jean-Christophe Marine strongly argues against the use of Cop1-inhibitory drugs. The protein Cop1 has -for a long time - been seen as an attractive drug target for cancer. But Jean-Christophe Marine found out that Cop1 acts as a tumor suppressor, and thus inhibits tumor formation. His new data will have direct implications for the development of cancer drug targets.

16 Mar 2011

Study sheds light on how signals from CSF help drive neural development

Cerebrospinal fluid, the fluid found in and around the brain and spinal cord, may play a larger role in the developing brain than previously thought, according to researchers at Children's Hospital Boston.

11 Mar 2011

Foreign-born scientists and artists receive sixth annual Vilcek Prize for Biomedical Science

The Vilcek Foundation is pleased to announce the 2011 winners of its annual prizes honoring the contributions of foreign-born scientists and artists.

24 Feb 2011

Hunk protein inhibition might provide new approach to treat HER2-positive breast cancer

Among women with breast cancer, approximately 25% have a subtype that is characterized by high levels of expression of the protein HER2. HER2-positive breast cancer tends to be more aggressive than other breast cancer subtypes.

15 Feb 2011

Research unmasks long sought stem cell origin of carcinoma

A constellation of different stem cell populations within our skin help it to cope with normal wear and tear. By constantly proliferating, the stem cells allow skin to replenish itself, allowing each cell to be replaced by a new one about once a month. But the normal cycle of division and death within one or more of these stem cell types can sometimes be derailed by genetic mishaps. Such events are believed to spawn carcinomas and other deadly skin cancers, which are the mostly frequently diagnosed cancers in the United States.

4 Feb 2011

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2011 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

2 Feb 2011

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

6 Jan 2011

Amira identifies novel pre-clinical candidate for autotaxin lysophosphatidic acid related program

Amira Pharmaceuticals, Inc. announced today that it has successfully identified a novel pre-clinical candidate for its newest lysophosphatidic acid (LPA)-related program, autotaxin. Autotaxin is an enzyme upstream from LPA receptors and has been implicated in a number of diseases including rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid cancers.

17 Dec 2010

New findings says TRIM24 protein plays active role in breast cancer formation

The recently identified TRIM24 protein plays an active role in pushing normal breast cells into rapid cell proliferation and, potentially, into breast cancer.

16 Dec 2010

Scientists discover potential strategy for pancreatic cancer therapy

By determining what goes missing in human cells when the gene that is most commonly mutated in pancreatic cancer gets turned on, Johns Hopkins scientists have discovered a potential strategy for therapy.

15 Dec 2010

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RONΔ160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.

19 Nov 2010

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

Elevated amounts of SP2 protein turn stem cells into cancerous tumors: Research

Researchers at North Carolina State University have found that the overproduction of a key protein in stem cells causes those stem cells to form cancerous tumors. Their work may lead to new treatments for a variety of cancers.

28 Oct 2010

Complete Genomics, SAIC-Frederick collaborate to validate somatic mutations from pediatric cancer cases

Complete Genomics Inc., a life sciences company focused on human genome sequencing, today announced a collaboration to identify and validate somatic mutations from 50 pediatric cancer cases from multiple research centers across the United States.

7 Sep 2010

hBD-3 biomarker helps early stage detection of oral cancer

Detecting oral cancer in its earliest stages can save the lives of the nearly 40,500 people diagnosed annually. But early detection has been difficult. Case Western Reserve University School of Dental Medicine researchers discovered a biomarker, called human beta defensin-3 (hBD-3), which may serve as an early warning. The defensin is present in all oral cancers and associated with the early stages of oral cancer.

23 Jul 2010

Keck School of Medicine receives grant for research on biomarker impact on breast cancer screening

Researchers at the Keck School of Medicine of the University of Southern California (USC) will test whether a set of blood-based biomarkers can assist mammography in the early detection of breast cancer with a $180,000 grant announced today from Susan G. Komen for the Cure®. The grant will fund research into whether specific biomarkers, or minute substances in the blood, can effectively distinguish breast cancer patients from their healthy counterparts and whether an inexpensive, less invasive screening strategy can be developed based on this approach.

15 Jul 2010

CWRU researchers discover biomarker for early warning of oral cancer

Detecting oral cancer in its earliest stages can save the lives of the nearly 40,500 people diagnosed annually. But early detection has been difficult.

14 Jul 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

New book provides comprehensive review of the functions of p53 family

The p53 tumor suppressor gene, the "guardian of the genome," protects cells against genotoxic stress but is mutated in many cancers. It encodes one of a family of proteins that regulate cell proliferation, differentiation, senescence, and cell death. Mutations in p53 allow cells to escape normal growth controls and thereby contribute to tumor malignancy.

24 Jun 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010